Cost-effectiveness of intensive treatment in Steno-2 study unveiled
Intensive, multifactorial treatment of type 2 diabetes can significantly improve microvascular, cardiovascular and mortality outcomes up to 20 years later, according to new research.
The Steno-2 study, which involved 160 people with type 2 diabetes and microalbuminuria, looked at the costs associated with the intensive and conventional treatments over the entire study period.
All the participants were were randomised to conventional or intensified multifactorial target-driven intervention for 7.8 years. Information on direct healthcare costs was retrieved from health registries, and the costs in the two groups of participants were compared by bootstrap t test analysis.
Over 21.2 years of follow-up, there was no significant difference in total direct medical costs between the groups; however, the mean cost per person-year was significantly lower in the intensive treatment group (€8725 vs €10 091; P=0.045). The lower cost was mainly driven by fewer inpatient admissions related to cardiovascular disease (P=0.0024).
Considering the substantial health benefits achieved, the authors conclude that intensive, multifactorial intervention in high-risk individuals with type 2 diabetes is highly feasible and cost-effective.
The study was published in the Diabetes & Primary Care journal. The read the findings in full, click here.